Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

New test for detecting small amounts of proteins in the blood

Researchers at the University of Pennsylvania School of Medicine have developed a paradigm-shifting method for detecting small amounts of proteins in the blood.

13 Mar 2006

Scientists fight leukaemia with 'natural killer' cells

Scientists at the University of the West of England and the Bone Marrow Transplant Unit at the Bristol Children's Hospital have just won funding for a two-year project aimed at improving the outcome of bone marrow stem-cell transplants in young leukaemia patients.

8 Mar 2006

Extensive study of natalizumab

Scientists have completed an extensive study of more than 3,000 patients who received a promising anti-inflammatory drug, natalizumab, that was linked to three cases of a serious brain infection in large clinical trials halted in early 2005.

7 Mar 2006

Selective T cell stimulation could help improve treatment of autoimmune disease and cancer

The findings could also be significant for developing new ways to help patients with autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, or juvenile diabetes.

23 Feb 2006

Monoclonal antibody targets key tumor growth factor

Monoclonal antibody targets key tumor growth factor; Successfully causes brain tumor regression and improves animal survival

19 Feb 2006

Targeted cancer therapies: Another step forward

While it is clear that the treatment of cancer has already begun to undergo a paradigm shift with the inclusion of innovative targeted therapies into current regimens, it would be wrong to assume these products will entirely replace traditional chemotherapy as the standard treatment for cancer sufferers.

22 Dec 2005

Targeted cancer therapies: Another step forward

22 Dec 2005

Anti-Abeta42 and Anti-Abeta40–specific monoclonal antibodies attenuate amyloid deposition in an Alzheimer disease mouse model

Current hypotheses suggest that it is the accumulation over time of amyloid beta peptide 1–42 (Abeta42) that triggers changes in the brain that lead to cognitive dysfunction in Alzheimer's disease.

13 Dec 2005

Herceptin - can healthcare afford this expensive drug?

New research into the cost of using the breast cancer drug Herceptin warns that healthcare authorities and the organisations advising them should not rush to prescribe it for early breast cancer without working out extremely carefully the budget implications and cost-effectiveness of the drug.

2 Dec 2005

New respiratory synctial virus treatment for at-risk infants under study

A new, enhanced-potency onoclonal antibody designed to keep the sniffles from turning into a devasting illness in at-risk babies is under study at the Medical College of Georgia Children's Medical Center.

14 Nov 2005

Substance found in evening primrose oil inhibits breast cancer gene

Gamma-linolenic acid (GLA), a substance in evening primrose oil and several other plant oils used in herbal medicine, inhibits action of Her-2/neu, a cancer gene that is responsible for almost 30 percent of all breast cancers, Northwestern University researchers report.

3 Nov 2005

Targeted drug delivery now possible using nanoparticle-apatamer conjugates

Ground-breaking results from researchers at Harvard Medical School and Massachusetts Institute of Technology (MIT), USA, disclosed at the 13th European Cancer Conference (ECCO) have shown for the first time that targeted drug delivery is possible using nanoparticle-apatamer conjugates.

3 Nov 2005

Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates

Ground-breaking results from researchers at Harvard Medical School and Massachusetts Institute of Technology (MIT), USA, disclosed at the 13th European Cancer Conference (ECCO) in Paris have shown for the first time that targeted drug delivery is possible using nanoparticle-apatamer conjugates.

1 Nov 2005

First study to confirm the benefit of anti-angiogenic therapy in patients with breast cancer

Results from the first and only interim analysis of an important trial assessing the potential of Herceptin (trastuzumab) to improve disease-free survival (DFS) in HER-2 positive breast cancer patients after adjuvant chemotherapy, have shown that Herceptin affords a significant survival advantage.

1 Nov 2005

New treatment advances for patients with follicular lymphoma

A newly published study recommends that doctors carefully choose their patients' initial therapies because there are significant differences in overall survival rates, according to researchers at the University of Rochester Medical Center's James P. Wilmot Cancer Center.

20 Oct 2005

Herceptin results "quite remarkable"

The targeted drug trastuzumab, or Herceptin, previously shown to prolong survival in advanced breast cancer, dramatically reduced the chances of recurrence in patients with early-stage disease when given for one year following standard chemotherapy.

19 Oct 2005

Hormone responsible for types of high blood pressure could also cause preeclampsia

Researchers at the University of Cincinnati (UC) Academic Health Center have found evidence of a hormone they say is responsible for certain types of high blood pressure (hypertension), and could also cause preeclampsia, a potentially dangerous condition that occurs during pregnancy.

17 Oct 2005

New monoclonal antibody that targets immune system B cells shows promise for treating leukemias

In studies with mice, treatment with a new monoclonal antibody that targets immune system B cells has shown considerable promise for treating leukemias, autoimmune diseases and transplant rejection, according to immunologists at Duke University Medical Center.

11 Oct 2005

Dengue and other viruses may have developed tricks that let them reproduce inside macrophages

A monoclonal antibody that can effectively treat mice infected with West Nile virus has an intriguing secret: Contrary to scientists' expectations, it does not block the virus's ability to attach to host cells. Instead, the antibody somehow stops the infectious process at a later point.

28 Sep 2005